The development of new digital strategies is a key mission of Rheumatology Department of the University Hospital Lausanne. This involves new digital biomarker such as DETECTRA, digital therapies (DTX) and artificial intelligence for image recognition or the prediction of disease activity and treatment response in arthritis.
Fresenius supports this endeavor with an unrestricted grant to support the digital biomarker program.
„We are happy to support research that leads to a better understanding of patient journeys in rheumatic diseases.“ says Graciella Pourcel from Fresenius. „Recognizing disease flares earlier and increasing the convenience for patients by measuring their disease at home will also support medical therapy“.
Prof. Thomas Hügle from the CHUV states „at the end, we as an academic center and Fresenius as pharmaceutical industry are keen to drive innovation and improve efficacy and safety of treatments on multiple levels“.
„It is important to create interoperable solutions that facilitate the daily life of patients with rheumatic diseases. We aim to reduce disease burden but also the administrative tasks of caregivers“ says Prof. Hügle.